Aquestive's Oral Epinephrine Film Gets A March 16, 2027 FDA Date As Revenue Falls 41%
The drugmaker kept its 2026 outlook and ended September with $90.3 million in cash as it prepares to launch Anaphylm if approved.
Aquestive Therapeutics, which develops oral-film medicines, said the FDA set a March 16, 2027 decision date for its resubmitted Anaphylm epinephrine film, while third-quarter revenue fell 41% to $7.6 million from $12.8 million a year earlier, according to an 8-K filed Tuesday.
A weaker quarter, a wider loss
The company blamed the revenue drop mainly on the quarterly swing in Suboxone product orders. Manufacture and supply revenue fell to $6.7 million from $11.5 million, partly offset by higher Ondif sales, and license and royalty revenue slipped to $0.8 million from $1.0 million.
The net loss widened to $16.5 million, or $0.13 per share, from $15.4 million, or $0.14 per share, a year earlier. Selling, general and administrative costs fell to $14.2 million from $15.3 million, helped by lower legal fees of about $1.5 million, but that did not offset the lost sales.
Adjusted EBITDA, a profit measure that strips out items such as stock pay and interest, showed a loss of $12.2 million versus $8.6 million in the third quarter of 2025. The company manufactured about 26 million doses, down from about 44 million a year earlier, though the total for the first nine months of 2026 was about 107 million, against about 108 million.
Full-year guidance is unchanged: revenue of $46 million to $50 million and an adjusted EBITDA loss of $35 million to $30 million.
The Anaphylm bet
Aquestive makes dissolvable films, including a postage-stamp-sized one it calls PharmFilm, and earns money by manufacturing licensed products such as Suboxone for partners. Anaphylm, an epinephrine film dissolved under the tongue for severe allergic reactions, is its lead product candidate.
The FDA rejected the application in a Complete Response Letter dated January 30, 2026. Aquestive resubmitted on September 16, 2026, and the FDA accepted it as complete and classified it as a Class 2 response. CEO Daniel Barber said, "we believe we have a clear path to making Anaphylm available to patients and caregivers, if approved."
The company expects to submit to Health Canada in the fourth quarter of 2026 and plans an EU filing in the first quarter of 2027.
Cash and the Libervant deal
Cash stood at $90.3 million on September 30, down from $121.2 million at the end of 2025. In October, Aquestive granted Eton Pharmaceuticals exclusive U.S. rights to Libervant, a diazepam film for seizure clusters, for $10 million upfront, up to $47.5 million in milestones and mid-teens royalties. Aquestive stays the manufacturer under a 20-year supply agreement.
Libervant's final FDA action has a goal date of March 23, 2027, and a separate application to add patients aged six to 11 has one of March 29, 2027. Aquestive holds its earnings call at 8:00 a.m. ET on Wednesday.
The FDA's March 16, 2027 goal date for Anaphylm is the next event that decides the company's lead product, with Libervant dates following on March 23 and March 29.
Sources
- 8-K Filing — Aquestive Therapeutics, Inc. (AQST) — SEC EDGAR
- Exhibit q32026-ex991earningsrelease.htm — Aquestive Therapeutics, Inc. 8-K exhibit — SEC EDGAR
- Exhibit thirdquarter2026earnings.htm — Aquestive Therapeutics, Inc. 8-K exhibit — SEC EDGAR